How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

452 results for

Dermal Filler Injection

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

glabellar frown lines Female or male, 30 to 65 years of age in good general health Women of childbearing potential must agree to use an effective method of birth control during the course of the study Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response Exclusion Criteria: Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic (...) Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2014 Clinical Trials

142. Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

course of the study Exclusion Criteria (A subject must not meet the following exclusion criteria in order to be eligible for enrollment in the stud)y: Previous treatment with botulinum toxin of any serotype in the forehead area within the last 8 months Previous treatment with any facial aesthetic procedure (e.g. injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months Previous insertion of permanent material in the glabellar area Planned treatment (...) of the lateral canthus (subjects can continue with their usual skin care routine) Inability to substantially lessen glabellar frown lines even by physically spreading them apart Marked facial asymmetry Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis History of facial nerve palsy Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin Any active infection in the area of the injection sites Medical condition that may affect neuromuscular function (e.g., myasthenia

2014 Clinical Trials

143. Injectable Bulking Agents for Incontinence (Treatment)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

144. Injectable Bulking Agents for Incontinence (Overview)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

145. Injectable Bulking Agents for Incontinence (Follow-up)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

146. Injectable Bulking Agents for Incontinence (Diagnosis)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

147. Collagen Injections

A, Hurwitz D, Ronel D. Malar augmentation with a polymethylmethacrylate-enhanced filler: assessment of a 12-month open-label pilot study. Aesthet Surg J . 2013 Mar. 33(3):421-30. . The American Society for Aesthetic Plastic Surgery Cosmetic Surgery National Data Bank Statistics. 2012; Jeong SH, Fan YF, Baek JU, et al. Long-lasting and bioactive hyaluronic acid-hydroxyapatite composite hydrogels for injectable dermal fillers: Physical properties and in vivo durability. J Biomater Appl . 2016 Sep. 31 (3 (...) , Zachary CB. Quality of life outcomes associated with treatment of human immunodeficiency virus (HIV) facial lipoatrophy. Int J Dermatol . 2016 Dec. 55 (12):1311-20. . Restylane Lyft with Lidocaine Injectable Gel Injectable Dermal Filler - P040024/S073. US Food and Drug Administration. Available at . Accessed: Oct 26, 2017. Hyaluronic Acid Wrinkle Treatments. Restylane Products. Available at . Accessed: Oct 26, 2017. Lacombe V. Sculptra: a stimulatory filler. Facial Plast Surg . 2009 May. 25(2):95-9

2014 eMedicine Surgery

148. Injectable Filler for Cheek Flattening

Injectable Filler for Cheek Flattening Injectable Filler for Cheek Flattening - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Injectable Filler for Cheek Flattening The safety and scientific validity (...) who have had prior exposure to any calcium hydroxylapatite, or any other filler, injection for any purpose in the 12 months preceding study enrollment through the duration of the study (excluding study drug). Subjects who have had a prior cosmetic procedure to improve malar eminence deficiency (i.e., rhytidectomy, lower eyelid surgery, cheek implants, CO2/erbium laser resurfacing, Thermage/Thermacool radiofrequency treatment) or who have visible scars that may affect evaluation of response

2010 Clinical Trials

149. A blanching technique for intradermal injection of the hyaluronic acid Belotero. (PubMed)

A blanching technique for intradermal injection of the hyaluronic acid Belotero. With the proliferation of dermal fillers in the aesthetic workplace have come instructions from various manufacturers regarding dermal placement. Determination of injection needle location in the dermis has in large part been based on physician expertise, product and needle familiarity, and patient-specific skin characteristics. An understanding of the precise depth of dermal structures may help practitioners (...) improve injection specificity. Unlike other dermal fillers that suggest intradermal and deep dermal injection planes, a new hyaluronic acid with a cohesive polydensified matrix may be more appropriate for the superficial dermis because of its structure and its high degree of integration into the dermis. To that end, the authors designed a small study to quantify the depth of the superficial dermis by means of ultrasound and histology. Using ultrasound resources, the authors determined the depths

2013 Plastic and reconstructive surgery

150. Autologous injectable dermis: a clinical and histological study. (PubMed)

Autologous injectable dermis: a clinical and histological study. No perfect solution yet exists for dermal fillers. The authors hypothesized that autologous dermis can be processed in an operator-friendly manner and adopted in selected patients as a filler, following the principle of replacing "like with like."The authors designed a prototype "cutting chamber" to morsel dermis into an injectable form. Autologous injectable dermis grafting was performed in 16 patients who underwent lip (...) reported transient palpable firmness for the first 6 months, which subsequently resolved. Histological examination of processed and injected dermis showed volume maintenance over time, effective revascularization of the mass, and structural reorganization with collagen bundles and nested fibroblasts reminiscent of reticular dermis. A transient inflammatory reaction was observed, consistent with the expected healing events.Use of autologous dermis as a filler substance for both aesthetic

2013 Plastic and reconstructive surgery

151. Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

the presence of any clinically significant bleeding disorder. Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological disease, or thyroid dysfunction) that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or give informed consent. Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before randomization. Treatment with botulinum toxin (...) Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2012 Clinical Trials

152. Use Of Three Commercial Preparations Of Injectable Hyaluronic Acid In Hands Rejuvenation

Drug: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine Phase 4 Detailed Description: This is a single center, phase IV, randomized, investigator-blind study of three different hyaluronic dermal filler injections for volume enhancing in the dorsum of the hands. As an investigator-blind study, only the investigators are unaware of which dermal fillers were injected in the dorsum of each hand. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial (...) for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Subjects agreeing to take part of all procedures of the study (including pre-test, filler injection, photographs, etc.), after being fully informed on the objectives and nature of the investigations; Written Informed Consent; Treatment-naive patients for fillers in hands; Subjects of both genders over 18 years; Fitzpatrick skin phototypes I to VI; Subjects presenting a similar loss of fatty tissue on both hands, at least of 2

2012 Clinical Trials

153. A Study to Assess Injection Comfort of Two Formulations of ATX-101

area, including but not limited to creams or ointments used to treat dermatologic conditions (e.g., steroids, capsaicin, retinoids, fluorouracil) within 7 days prior to Baseline. Treatment with radio frequency, laser procedures, chemical peel, or dermal fillers in the neck or chin area within 12 months before dosing or botulinum toxin injections within 6 months prior to Baseline. Previous enrollment into this trial or treatment with ATX-101 or agents containing deoxycholate. Treatment (...) A Study to Assess Injection Comfort of Two Formulations of ATX-101 A Study to Assess Injection Comfort of Two Formulations of ATX-101 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess

2011 Clinical Trials

154. Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

, or thyroid dysfunction) that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or provide informed consent. Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before randomization, or botulinum toxin injections in the neck or chin area within 6 months before randomization. History of sensitivity to any components of the study material or to topical or local (...) Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2011 Clinical Trials

155. Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

, or thyroid dysfunction) that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or provide informed consent. Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before randomization, or botulinum toxin injections in the neck or chin area within 6 months before randomization. History of sensitivity to any components of the study material or to topical or local (...) Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2011 Clinical Trials

156. Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections

Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Outcomes (...) and Patient Experience After Soft Tissue Dermal Filler Injections The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01034956 Recruitment Status : Completed First Posted : December 18, 2009 Last Update Posted : May 1, 2012 Sponsor: The New York Eye & Ear Infirmary Collaborator: Thomas Jefferson University

2009 Clinical Trials

157. The risk of alar necrosis associated with dermal filler injection. (PubMed)

The risk of alar necrosis associated with dermal filler injection. Injection of dermal fillers is one of the most commonly performed cosmetic procedures. Serious complications from fillers are rare but potentially devastating to patients and physicians. Skin necrosis, such as nasal alar necrosis, is one of the most feared serious complications of dermal fillers, but there is a paucity of literature on the incidence of such events, as well as potential treatment options.We present a review (...) of the literature and three cases of nasal alar necrosis after dermal filler injection.Nasal alar necrosis associated with dermal filler injection is a rare event. Proper technique and recognition of risk factors may reduce the incidence of this complication. Physicians should be aware of early intervention and treatment options should impending necrosis become apparent.

2009 Dermatologic Surgery

158. Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler

Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01012661 Recruitment Status : Completed First Posted : November 13, 2009 Results First Posted : January 15, 2010 Last Update Posted : April 26, 2013 Sponsor: Merz North America, Inc

2009 Clinical Trials

159. Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color

Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01012388 Recruitment Status : Completed First Posted : November 13, 2009 Results First Posted : December 23, 2009 Last Update

2009 Clinical Trials

160. Dermal filler injection: a novel approach for limiting infarct expansion. (PubMed)

Dermal filler injection: a novel approach for limiting infarct expansion. Early infarct expansion after coronary occlusion compromises contractile function in perfused myocardial regions and promotes adverse long-term left ventricular (LV) remodeling. We hypothesized that injection of a tissue-expanding dermal filler material into a myocardial infarction (MI) would attenuate infarct expansion and limit LV remodeling.Fifteen sheep were subjected to an anteroapical MI involving approximately 20 (...) % of the LV followed by the injection of 1.3 mL of a calcium hydroxyapatite-based dermal filler into the infarct. Real-time three-dimensional echocardiography was performed at baseline, 30 minutes after MI, and 15 minutes after injection to assess infarct expansion. Sixteen additional sheep were subjected to the same infarction and followed echocardiographically and hemodynamically for 4 weeks after MI to assess chronic remodeling. Eight animals had injection with dermal filler as described above

Full Text available with Trip Pro

2009 Annals of Thoracic Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>